Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

Evanthia Galanis(The University of Texas at San Antonio Health Science Center), Daniel J. Walsh(The University of Texas at San Antonio Health Science Center)
Journal of Clinical Oncology
July 6, 2005
10.1200/jco.2005.23.622
Cited by 695

Related Papers

A phase 1 and randomized, placebo‐controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872
|Cancer|2019|70
Immunostimulatory bacterial antigen–armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy
|Journal of Clinical Investigation|2021|61